Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Ability Biologics

start up
Canada - Montreal, Quebec
  • 07/12/2023
  • Seed
  • $12,000,000

Our Mission:
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.

The premier biotherapeutic targeting company

Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.

We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.


Related People

Giles DayCo Founder

Giles Day United States - South San Francisco, California

N/A